Case Report and Systematic Review of the Literature

Giant Petroclival Primary Intradural Chordoma: Case Report and Systematic Review of the Literature

Fahad AlOtaibi1,2 Marie-Christine Guiot3 Thierry Muanza4 Salvatore Di Maio1

1 Division of Neurosurgery, Department of Radiation Oncology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada
2 Department of Neurosurgery, National Neuroscience Institute, King Fahad Medical Center, Riyadh, Saudi Arabia
3 Department of Neuropathology, McGill University, Montreal Neurological Institute, Montreal, Quebec, Canada
4 Department of Radiation Oncology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada

Address for correspondence Salvatore Di Maio, MDCM, FRCS(C), Division of Neurosurgery, McGill University, Jewish General Hospital, Pavilion E, Room 929, 3755 Côte-Sainte-Catherine Road, Montreal, QC H3T 1E2, Canada (e-mail: sdimaio@jgh.mcgill.ca).

J Neurol Surg Rep 2014;75:e160–e169.

Abstract

Background Chordomas are rare, locally aggressive neoplasms thought to arise from notochordal remnants in the axial skeleton. Primary intradural chordomas are considered to be extremely rare. In this article a giant intradural petroclival chordoma is presented, and a synthesis of the available literature is performed to measure overall survival (OS) and recurrence-free survival (RFS) and to identify prognostic factors.

Methods A systematic Medline review yielded 47 patients with purely intradural tumors from 38 publications including 39 chordomas, 8 cases of ecchordosis physaliphora, and 1 case with features of both. The 5-year OS and RFS were calculated based on the Kaplan-Meier method. Risk factors for progression or mortality were analyzed using binomial logistic regression.

Results Maximal tumor diameter varied from 1.5 to 6.0 cm (mean: 3.2 cm). Tumors were located predominantly in the prepontine area (66.7%). Combined 5-year Kaplan-Meier OS and RFS were 77% ± 11% and 74% ± 11%, respectively. Incomplete surgical resection, larger tumor diameter, and an elevated Ki-67 index were statistically more frequent in cases of recurrence and mortality.

Conclusions Based on a systematic literature review, the behavior of primary intradural chordomas may be closer to typical chordomas than was previously thought.

Keywords
- chordoma
- notochord
- skull base neoplasms
- brainstem neoplasms

Introduction

Chordomas are rare locally aggressive neoplasms of notochordal origin, constituting 2 to 4% of primary bone tumors.1 In contrast to ecchordosis physaliphora (EP), which are usually small incidentally discovered rests of tissue within the clivus or retroclival space, cranial base chordomas mostly arise extradurally and produce symptoms secondary to growth and bony destruction. Rare cases of extrasosseous intradural chordoma have been reported and generally considered to have a more favorable prognosis relative to typical chordomas.2–4 We report a case of a giant intradural chordoma lacking bony involvement. We furthermore performed a systemic review of the literature to (1) assess for clinical, histologic, and radiologic differences between intradural chordoma and EP; (2) summarize overall survival (OS) and recurrence-free survival (RFS) data; and (3) identify risk factors impacting 5-year RFS and OS in patients with intradural chordomas and EP.

received February 12, 2014 accepted April 9, 2014 published online June 26, 2014

DOI http://dx.doi.org/10.1055/s-0034-1378157. ISSN 2193-6358.

© 2014 Georg Thieme Verlag KG Stuttgart · New York
Materials and Methods

The current study is a systematic review of the literature applying the Preferred Reporting Items for Systematic Reviews guidelines. All studies included were case reports or small primarily retrospective case series.

Search Strategy

A systematic electronic article search was conducted through Medline between 1974 and 2013, using the Medical Subject Heading terms chordoma, eccchordosis physaliphora, notochord, bone neoplasms, and skull base neoplasms. Titles and abstracts were then reviewed to identify cases of intradural chordomas or eccchordosis physaliphora. A manual search was also conducted from the reference lists of selected articles to identify additional studies. Of these articles, a full-text review was performed by two coauthors independently (F.A. and S.D.), applying inclusion and exclusion criteria to obtain a final group of included studies. Studies were included if (1) they reported patients with histologically confirmed intradural chordomas or eccchordosis physaliphora; (2) patients were symptomatic and/or had large (>3 cm maximal diameter) or growing tumors; and (3) tumors were found to have bony stalk without evidence of bony destruction. Articles were excluded if (1) patients were asymptomatic and/or had small (<1 cm maximal diameter) tumors; (2) if the article was an autopsy, nonsurgical, or pure radiologic series; and (3) if the patient was treated in the era before computed tomography (CT) or magnetic resonance imaging (MRI).

Data Collection

After a final list of articles was assembled, individual patient data were extracted and compiled on to a master database. Patient age, sex, tumor size, location, pathologic diagnosis, presenting symptoms, extent of surgical resection, adjuvant therapy, follow-up duration, recurrence, and mortality were all recorded.

Statistical Analyses

From the compiled patient database, 5-year overall OS and RFS were calculated using the Kaplan-Meier method. Risk factors for progression or mortality were analyzed using binomial logistic regression. An assessment of risk of bias was not possible for this study. A p value <0.05 was considered to be statistically significant. Statistics were performed using IBM SPSS v.21.0 (IBM, Inc, Armonk, New York, United States).

Results

An initial systematic Medline search yielded 416 publications. After screening based on title and abstract review and applying the previously described inclusion and exclusion criteria, there were 38 publications including 47 patients. The details of each study are tabulated in Appendix A, and subject demographics from the literature cases and ours (48 patients total) are summarized in Table 1. Patient age ranged from 9 to 76 years (mean: 42.8 years) and maximal tumor diameter varied from 1.5 to 6 cm (mean: 3.2 cm). Tumors were located predominantly in the prepontine (66.7%) and sellar/suprasellar/hypothalamic (18.8%) areas, and the postoperative follow-up ranged from 3 weeks to 144 months (mean: 30.2 months). Pathologic diagnosis was reported as chordoma in 39 cases and eccchordosis physaliphora in 8 cases. In one series of two patients in which the distinction of EP versus chordoma was not explicitly made, the diagnosis was inferred based on the histologic description provided in the manuscript (one EP and one chordoma). In one case, histologic features of both chordoma and EP were reported. Of 43 of 48 patients for whom extent of surgical resection was reported, 25 had complete or near-complete resection, whereas 18 had subtotal removal. Information regarding adjuvant radiation therapy was available in 41 of 48 cases. Adjuvant radiotherapy was administered in seven cases; all of these patients had undergone subtotal resections. In most cases, radiation therapy was not given (32/41 cases) or given only at recurrence (2/41 cases). None of the cases had bony involvement. In four cases, a bony stalk was observed connecting the intradural tumor to the clivus but without frank bony destruction. In the remaining cases, a bony stalk was absent. Clinical presentation varied between cases but was mainly secondary to brainstem involvement: 52.5% of patients experienced headaches, cranial nerve palsies were observed in 41.5%, and gait disturbance in 30%. Most of the cases presented with subacute to chronic symptoms, and only a few presented with acute neurologic deterioration related to tumor hemorrhage. One case of EP presented with fatal diffuse nonaneurysmal subarachnoid hemorrhage, and another chordoma with intratumor hemorrhage.

Survival data were available for 32 of 48 patients. Based on the Kaplan-Meier survival analysis of the compiled available individual patient data, 5-year RFS was 74% ± 11%, and mean RFS was 112.0 months (95% confidence interval [CI]: 86.6–137.5 months) (Fig. 1A). The 5-year OS was 77% ± 11%; excluding 30-day surgical mortality, 5-year OS was 87% ± 7%. Mean OS was 115.9 months (95% CI, 90.7–141.2 months) (Fig. 1B). The 5-year OS for patients undergoing complete resection was 92% ± 8%, compared with 63% ± 18% for those with subtotal resection (p = 0.00004). The 5-year RFS for patients undergoing complete resection was 83% ± 15%, compared with 64% ± 15% for those with subtotal resection (p = 0.00290). Patients who developed recurrence had a larger tumor diameter (4.3 ± 0.5 cm versus 3.2 ± 1.2 cm; p = 0.0390) and a more elevated Ki-67 index (6.83 ± 1.21% versus 1.03 ± 1.84%; p < 0.001) compared with those who did not (Tables 2 and 3). Similarly, patients who died had a larger tumor diameter (4.8 ± 0.8 cm versus 3.2 ± 1.2 cm; p = 0.039) and a more elevated Ki-67 index (6.83 ± 1.21% versus 1.03 ± 1.84%; p < 0.001) than those who survived. No other recurrence or survival-related risk factors analyzed were found to be statistically significant.

Case Illustration

The patient is a 51-year-old right-handed man who works as a janitor. He presented with a 2-year history of balance difficulty and initially vertical diplopia, followed by diplopia in all directions. The patient is a 51-year-old right-handed man who works as a janitor. He presented with a 2-year history of balance difficulty and initially vertical diplopia, followed by diplopia in all directions. The patient is a 51-year-old right-handed man who works as a janitor. He presented with a 2-year history of balance difficulty and initially vertical diplopia, followed by diplopia in all directions.
vectors. He also complained of decreased hearing and facial sensation on the left side. On examination, he had near-complete ophthalmoplegia in the left eye, as well as left ptosis and a fixed, dilated pupil. There was 20% subjective sensation in the left V1–3 dermatomes. His gait was ataxic, and he had psychomotor slowing as well as mild word-finding difficulty. He had diffuse hyperreflexia, and positive Hoffman and Babinski reflexes. There was bilateral upper and lower extremity dysmetria.

His magnetic resonance imaging (MRI) demonstrated a giant left petroclival intradural lesion extended from the jugular foramen caudally and superior to the tentorium to the parasellar space and cavernous sinus (►Fig. 2). A head computed tomography (CT) demonstrated a lack of any bony destruction, remodeling, or tumoral involvement. There was severe effacement of the brainstem and partial encasement of the basilar and ipsilateral vertebral arteries. The lesion appeared lobulated, hyperintense on T2, hypointense on T1, and there was only mild heterogeneous enhancement. The preoperative differential diagnosis included atypical meningioma, schwannoma, neuroepithelial cyst, and chordoma. A preoperative CT scan did not demonstrate any bony involvement of the tumor.

**Operation**

The patient underwent a left-sided posterior transpetrosal approach. Intraoperative monitoring of long tract motor- and sensory-evoked potentials, as well as brainstem auditory evoked responses and cortically evoked facial nerve motor-evoked potentials was performed. The presigmoid dura was opened from above the jugular bulb across the superior petrosal sinus and to the temporal lobe. The vein of Labbé was seen coursing posteriorly to drain into the transverse sinus. The tentorium was divided posterior to the course of the trochlear nerve. An expansile mass was seen medial to the trochlear, trigeminal and VII–VIII nerves. It was debulked and

| No. of subjects | 48 (25 males/20 females/3 not specified) |
|-----------------|----------------------------------------|
| Mean age        | 42.8 ± 17.9 y (range: 9.0–76.0 y)       |
| Follow-up       | 30.2 ± 33.0 mo (range: 0.75–144.0 mo)   |
| Tumor location  |                                        |
| Preoptine       | 32/48 (66.7%)                           |
| Sellar/suprasellar/hypothalamus | 9/48 (18.8%)                           |
| Other (cerebellar, foramen magnum, tentorial, pineal, petroclival, disseminated) | 7/48 (14.6%)                           |
| Maximal tumor diameter | 3.2 ± 1.3 cm (range: 1.5–6.0 cm)       |
| Reported histology | Chordoma: 38/48 (79.2%)              |
|                 | EP: 9/48 (18.8%)                       |
|                 | Chordoma and EP 1/48 (2.1%)            |
| Presenting symptoms |                                        |
| Cranial nerve palsy | 17/41 (41.5%)                          |
| Headaches       | 21/40 (52.5%)                          |
| Intraventricular hemorrhage | 1/40 (2.5%)                           |
| Gait disturbance | 12/40 (30.0%)                          |
| Tinnitus        | 3/40 (7.5%)                            |
| Speech disturbance | 3/40 (7.5%)                           |
| Motor weakness  | 7/40 (17.5%)                           |
| Memory disturbance | 6/40 (15.0%)                           |
| Visual signs or symptoms | 9/40 (22.5%)                           |
| Sensory symptoms | 3/40 (7.5%)                            |
| Adjuvant radiation therapy |                                    |
| Upfront         | 7/41 (17.0%)                           |
| At recurrence   | 2/41 (4.9%)                            |
| None            | 32/41 (78.0%)                          |
| Information not specified | 7/48                                   |

Abbreviation: EP, echordosis physaliphora.
mobilized without difficulty. Superiorly, the tumor was resected up to the cavernous sinus; however, the visualization offered by the approach was inadequate and a small remnant was believed to have been left behind. Medially, the tumor dissected very well off the brainstem and basilar artery. The tumor was followed into Meckel cave, which was partially unroofed and packed with Surgicel and Tisseel following tumor removal. The remainder of the tumor was removed, and intraoperative monitoring remained pristine throughout the case.

Pathology
All the histologic sections examined showed the presence of a tumoral proliferation composed of cells with vacuolated cytoplasm and areas resembling cartilage (Fig. 3). In some areas, the cells formed anastomotic cords floating in a chondroid type of matrix. Cytokeratin immunohistochemistry was strongly positive, and there was focal but definite positivity for both S-100 and brachyury. The Ki-67 index was very low (<0.5%), with only a few positive nuclei. Final diagnosis was consistent with chordoma.

Postoperative Course
Postoperative MRI (Fig. 2) demonstrated complete resection of the posterior fossa tumor with an expected small remnant within the cavernous sinus. His postoperative course was complicated by a single partial complex seizure on postoperative day 1, for which antiepileptic medication was not started, and there were no further episodes. He also developed a pseudomeningocele that resolved spontaneously without specific intervention. His ataxia, weakness, psychomotor slowing, ptosis, and diplopia all resolved postoperatively, although clinically he continues to have a trochlear nerve palsy.

At 3 months postoperatively, the patient received fractionated stereotactic radiotherapy (fSRT) with an intensity-modulated radiotherapy RAPID Arc system (Varian Medical Systems, Palo Alto, California, United States) using MRI fusion. A total dose of 52 Gy was delivered in 28 fractions. His last follow-up MRI at 12 months from surgery demonstrated no recurrence of the tumor.

Discussion
Luschka first described his finding of pathologic ectopic notochordal tissue at the posterior clivus in 1856. In 1857, Virchow gave the first microscopic description and termed the lesion *echondrosis physaliphora*, believing it to be a process affecting the cartilage of the sphenoid-occipital

Table 2 Risk factors associated with recurrence in 32/48 patients with intradural chordoma or ecchordosis physaliphora

| Risk Factor          | Recurrence (n = 5) | No recurrence (n = 27) | p value |
|----------------------|--------------------|------------------------|---------|
| Maximal diameter, cm| 4.3 ± 0.5          | 3.1 ± 1.3              | 0.010   |
| Age, y               | 46.0 ± 16.4        | 38.2 ± 19.0            | 0.381   |
| Sex                  | 1 male / 4 females | 17 males / 8 females   | 0.130   |
| Enhancement          | 5 yes / 0 no       | 18 yes / 7 no          | 0.355   |
| Pathology            | 5 chordoma / 0 EP  | 22 chordoma / 5 EP     | 0.284   |
| Bony stalk           | 0 yes / 5 no       | 3 yes / 24 no          | 0.424   |
| Ki-67, %             | 5.12 ± 3.56        | 1.08% ± 1.88           | 0.004   |

Abbreviation: EP, ecchordosis physaliphora.
synchondrosis. One year later, Müller correctly proposed a notochordal origin, and in 1894, Ribbert and Steiger coined the term ecchordosis to reflect a presumed notochordal origin of these lesions. EP is considered to be an ectopic notochordal remnant lacking internal proliferative potential. Whether EP is the precursor of skull base chordoma remains controversial. Furthermore, debate persists regarding whether large symptomatic EP is truly distinct from intradural chordoma, or whether they are terms describing the same pathologic entity.

Wolfe and Scheithauer et al proposed the term intradural chordoma should be for all lesions, including EP, whereas Rodríguez et al argued that all instances of symptomatic, intradural, extraosseous physaliphora cell growth should be classified as giant or symptomatic EP so long as the existence of an intradural chordoma is not definitely proved. Histologically, EP and intradural chordoma display many similarities including the presence of typical “vacuolated cells” and positive staining for Brachyury and Galectin-3. Pragmatically speaking, in many cases the pathologic diagnosis is influenced and supported by the clinical picture and radiologic findings. Specific histologic differences have been proposed including a smaller cell number and absence of extracellular mucous-like matrix or necrotic cells in EP. Wang et al described the volume of EPs to be characteristically less than intradural chordomas, with the largest reported diameter < 2 cm; however, there are literature instances of so-called EP with diameters of 4 cm, 3 cm, and 3 cm. Other distinguishing features proposed include the presence of clinical symptoms including those related to brainstem compression and/or cranial nerves palsies in true chordomas, a low Ki-67 index in EP, as well as contrast enhancement in true chordomas versus lack of

### Table 3

| Risk Factor                          | Nonsurviving (n = 4) | Surviving (n = 28) | p value |
|--------------------------------------|----------------------|--------------------|---------|
| Maximal diameter, cm                 | 4.8 ± 0.8            | 3.2 ± 1.2          | 0.039   |
| Age, y                               | 39.8 ± 0.9 cm        | 39.5 ± 19.6        | 0.980   |
| Sex                                  | 1 male/3 females     | 16 males/10 females| 0.170   |
| Enhancement                          | 4 yes/0 no           | 21 yes/7 no        | 0.467   |
| Pathology                            | 4 chordoma/0 EP      | 26 chordoma/2 EP   | 0.358   |
| Bony stalk                           | 0 yes/5 no           | 3 yes/24 no        | 0.492   |
| Ki-67, %                             | 6.83 ± 1.21          | 1.03 ± 1.84        | < 0.001 |

Abbreviation: EP, ecchordosis physaliphora.

**Fig. 2** Preoperative (A) sagittal T1, (B) axial T2, and (C) coronal T1 magnetic resonance imaging (MRI) with gadolinium demonstrating a large left petroclival intradural chordoma. (D) Preoperative computed tomography (CT) did not demonstrate any bony involvement. (E–G) Postoperative MRI showing near-complete resection with a likely small residual in the left cavernous sinus (F, arrow). (H) Postoperative CT showing skeletonization of semicircular canals. Preoperative CT did not disclose any bony involvement.
The presence of a bony stalk was reported in several cases; however, we did not find it to be a distinguishing feature of EP versus chordoma, nor did it appear to affect prognosis.

Based on prior case reports and small series, intradural chordomas have generally been considered to have a more favorable prognosis and a different biologic behavior relative to typical cranial base chordomas. The data from our systematic review suggest that both 5-year RFS and OS appear to be comparable with typical chordomas, particularly following a complete surgical resection. In a recent meta-analysis of cranial base chordomas, 5-year RFS was 87% in patients with complete resection compared with 50% in patients with incomplete resection, and 5-year OS was 95% with complete resection versus 71% without. This is similar to our study, in which 5-year RFS for patients undergoing complete resection was 83% ± 15, compared with 64% ± 15% for those with subtotal resection, and in which 5-year OS was 92% ± 8% with complete resection, compared with 63% ± 18% with incomplete resection (p < 0.001). Thus although a gross total resection may be more feasible for true intradural chordomas, their biologic behavior may nevertheless be similar to classic skull base chordomas and is reflected by similar survival of both subtypes after complete and incomplete resections.

The cellular and molecular mechanisms by which chordomas effectuate bony invasion and overall aggressiveness remain poorly understood, and in light of the relative rarity of intradural chordomas and EP, differentiating features are as yet lacking. Proteases may be implicated in bony destruction in chordomas. Matrix metalloproteinases and cathepsin K have been investigated as potential mediators; their increased expression appear related to worse prognosis. Adhesion proteins may also mediate tumor invasiveness in chordomas. Upregulation of N-cadherin and downregulation of E-cadherin may be correlated with worse clinical behavior of some chordomas. Upregulation of specific proto-oncogenes have also been evaluated, including c-MET and hepatocyte growth factor expression. Fascin overexpression was also correlated with increased chordoma invasiveness and dural penetration, implicating increased cell motility as a potential mechanism. Increased telomerase activity also appears to correlate with chordoma recurrence and possible aggressiveness. The cellular proliferative potential, as measured by the Ki-67 staining index, has been reported to distinguish EP from chordoma. Reportedly cases of EP typically have a Ki-67 index < 1%, whereas in chordoma it is > 2%. Accordingly, all the cases included in our systematic review demonstrated a Ki-67 index < 2% in EP.

Our study is subject to several important limitations. All included studies are of a retrospective nature composed primarily of case reports and a few small case series, and they subject our meta-analysis to potential publication bias. Heterogeneity in the compiled cohort was observed due to local differences in the use of adjuvant radiation therapy, and often unclear justification for the pathologic distinction between EP and true chordoma. The histologic distinguishing features between chordoma and EP are unclear; there is heterogeneity in the pathologic distinction of intradural chordomas and EP.
cases included in our literature synthesis. Finally, the overall small population limits statistical power.

**Conclusion**

Intradural cranial base chordomas are extremely rare. There is lack of uniform agreement regarding the distinguishing features of chordoma and ecchordosis physaliphora, particularly for large symptomatic tumors. Based on our meta-analysis, the clinical behavior of intradural chordomas may be closer to typical cranial base chordomas than was previously recognized. This finding may influence clinical management, particularly the use of adjuvant radiation therapy as in our case illustration.

**Disclosure**

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this article.

**References**

1. Warnick RE, Raisanen J, Kaczmar T Jr, Davis RL, Prados MD. Intradural chordoma of the tentorium cerebelli. Case report. J Neurosurg 1991;74(3):508–511
2. Yuh J, Akusa T, Tomosugi T, Kusumoto K, Awa H, Uetsuikara K. A case of clival chordoma without bone destruction. [in Japanese]. No Shinkei Geka 1986;14(4):547–552
3. Uda T, Ohata K, Takami T, Hara M. An intradural skull base chordoma presenting with acute intratumoral hemorrhage. Neurol India 2006;54(3):306–307
4. Masui K, Kawai S, Yonezawa T, Fujimoto K, Nishi N. Intradural retroclival chordoma without bone involvement—case report. Neurol Med Chir (Tokyo) 2006;46(11):552–555
5. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535
6. Wolfe JT III, Scheithauer BW. “Intradural chordoma” or “giant ecchordosis physaliphora”? Report of two cases. Clin Neuropathol 1987;6(3):98–103
7. Rodríguez L, Colina J, López J, Molina O, Cardozo J. Intradural preoptine growth: giant ecchordosis physaliphora or extraossous chordoma? Neuropathology 1999;19:336–340
8. Fracasso T, Brinkmann B, Paulus W. Sudden death due to subarachnoid bleeding from ecchordosis physaliphora. Int J Legal Med 2008;122(3):225–227
9. Luschka H. Die altersveränderungen der Zwischenwirbelknochel. Virchows Arch 1866;9:311–327
10. Vichow RLK. Untersuchungen über die Entwickelung des Schädelgrundes im gesunden und krankhaften zustand: und über den einfluss derselben auf Schädelform, Gesichtsbildung und Gehirnbau. Berlin, Germany: Reimer; 1857
11. Müller H. Uber das Vorkommen von Resten der Chorda dorsalis bei Menschen nach der Geburt und über ihr Verhältnis zu den Gallertgewächslen am Clivus. Ztschr F Rat Med 1858; 2:202–229
12. Ribbert H, Steiner H. Über die Eccordrosis physalifera sphenoooccipitalis. Zentralbl Allg Pathol Anat 1894;5:457–461
13. Mathews W, Wilson CB. Ectopic intrasellar chordoma. Case report. J Neurol Surg 1974;40(2):260–263
14. Mapstone TB, Kaufman B, Ratcleson RA. Intradural chordoma without bone involvement: nuclear magnetic resonance (NMR) appearance. Case report. J Neurosurg 1983;59(3):535–537
15. Bergmann M, Abdalla Y, Neubauer U, Schildhaus HU, Probst-Cousin S. Primary intradural chordoma: report on three cases and review of the literature. Clin Neuropathol 2010;29(3):169–176
16. Wang L, Wu Z, Tian K, Li G, Zhang J. Clinical and pathological features of intradural retroclival chordoma. World Neurosurg 2013; February 13 (Epub ahead of print)
17. Takeyama J, Hayashi T, Shirane R. Notochordal remnant-derived mass: ecchordosis physaliphora or chordoma? Pathology 2006;38(6):599–600
18. Ling SS, Sader C, Robbins P, Rajan GP. A case of giant ecchordosis physaliphora: a case report and literature review. Otol Neurotol 2007;28(7):931–933
19. Amer HZ, Hameed M. Intrasosseous benign notochordal cell tumor. Arch Pathol Lab Med 2010;134(2):283–288
20. Mehlert F, Beschrorner R, Küker W, Hahn U, Nägele T. Retroclival ecchordosis physaliphora: MR imaging and review of the literature. AJNR Am J Neuroradiol 2004;25(10):1851–1855
21. Di Maio S, Temkin N, Ramanathan D, Sekhar LN. Current comprehensive management of cranial base chordomas: 10-year meta-analysis of observational studies. J Neurosurg 2011;115(6):1094–1105
22. Naka T, Kuester D, Boltze C, et al. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type 1 in skull base chordoma. Hum Pathol 2008;39(2):217–223
23. Haeckel C, Krueger S, Kuester D, et al. Expression of cathepsin K in chordoma. Hum Pathol 2000;31(7):834–840
24. Triana A, Ken C, Wolfe D, Hazan R. Cadherins and catenins in clival chordomas: correlation with expression of tumor aggressiveness. Am J Surg Pathol 2005;29(11):1422–1434
25. Naka T, Kuester D, Boltze C, et al. Expression of hepatocyte growth factor and e-MET in skull base chordoma. Cancer 2008;112(1):104–110
26. Gao Z, Zhang Q, Kong F, et al. Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion. Med Oncol 2012;29(4):2438–2444
27. Pallini R, Maira G, Pierconti F, et al. Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg 2003;98(4):812–822
28. Stamm FC, Kamphorst W. Eccordosis physaliphora as a cause of fatal pontine hemorrhage. Eur Neurol 1982;21(2):90–93
29. Vaquero J, Martínez R, Rossi E, Bravo G. Chordoma. Neurosurgery 1983;13(6):737–738
30. Katayama T, Tsuchikawa T, Hirasawa T, Takahata T, Nemoto N. Intradural extraosseous chordoma in the foramen magnum region. Case report. J Neurosurg 1991;75(6):976–979
31. Hardie RC. Magnetic resonance appearance of a rare intradural chordoma. Wis Med J 1992;91(11):627–628
32. Commins D, Baran GA, Mollestone M, Vollmer D. Hypothalamic chordoma. Case report. J Neurosurg 1994;81(1):130–132
33. Tashiro T, Fukuda T, Inoue Y, et al. Intradural chordoma: case report and review of the literature. Neuroradiology 1994;36(4):313–315
34. Wanabuchi M, Uede T, Ishiguro M, Tatewaki K, Kurokawa Y, Yoshida Y. A case of suprasellar intradural chordoma. [in Japanese]. No Shinkei Geka 1994;22(3):269–272
35. Akimoto T, Takeda H, Hashimoto T, Haraoa K, Ito H. A surgical case of ecchordosis physaliphora. [in Japanese]. No Shinkei Geka 1996;24(11):1021–1025
36. Nishigaya K, Kaneko M, Ohashi Y, Nukui H. Intradural retroclival chordoma without bone involvement: no tumor regrowth 5 years after operation. Case report. J Neurosurg 1998;88(4):764–768
37. Toda H, Kondo A, Iwasaki K. Neuoradiological characteristics of ecchordosis physaliphora. Case report and review of the literature. J Neurosurg 1998;89(5):830–834
Korinth M, Schönrock L, Mayfrank L, Gilsbach JM. Primary intradural pontocerebellar chordoma metastasizing in the subarachnoid spinal canal. Zentralbl Neurochir 1999;60(3):146–150

Danilewicz B, Danilewicz M, Czepko R, Stachura K. Intradural clivus chordoma: surgical treatment with no tumor regrowth 12 years after surgery. [in Polish]. Przegl Lek 2000;57(3):178–180

Choo YS, Joo SW, Noh SJ, Lee SI. Intradural retroclival chordoma. J Korean Neurosurg Soc 2009;46(2):152–155

Chang SW, Gore PA, Nakaji P, Rekate HL. Juvenile intradural chordoma: case report. Neurosurgery 2008;62(2):E525–E526; discussion E527

Alkan O, Yildirim T, Kizilkiliç O, Tan M, Cekinmez M. A case of ecchordosis physaliphora presenting with an intratumoral hemorrhage. Turk Neurosurg 2009;19(3):293–296

Choo YS, Joo SW, Noh SJ, Lee SI. Intradural retroclival chordoma. J Korean Neurosurg Soc 2009;46(2):152–155

Ciarpaglini R, Pasquini E, Mazzatenta D, Ambrosini-Spaltro A, Sciarretta V, Frank G. Intradural clival chordoma and ecchordosis physaliphora: a challenging differential diagnosis: case report. Neurosurgery 2009;64(2):E387–E388; discussion E388

Bhat DI, Yasha M, Rojin A, Sampath S, Shankar SK. Intradural clival chordoma: a rare pathological entity. J Neurooncol 2010;96(2):287–290

Ito E, Saito K, Nagatani T, et al. Intradural cranial chordoma. World Neurosurg 2010;73(3):194–197; discussion e31

Jiagang L, Yanhui L, Xueying S, Qing M. Intradural suprasellar chordoid chordoma. J Clin Neurosci 2010;17(3):402–403

Figueiredo EG, Tavares WM, Welling L, Rosemberg S, Teixeira MJ. Ectopic pineal chordoma. Surg Neurol Int 2011;2:145

Anderson S, Sato Y, Kirby P, Buatti JM, Menezes A. Disseminated subarachnoid chordoma: long-term favorable follow-up of a pediatric patient. Pediatr Radiol 2012;42(7):878–880

Kim SK, Kim YH, Park CK, Kim MA, Park SH. Intracranial intradural chordoma presenting with intraventricular hemorrhage. Clin Neurol Neurosurg 2012;114(8):1189–1192
### Appendix A: Summary of included articles

| Study | Country of origin | Tumor Location | Age, y/Sex | Extent of resection | Adjuvant therapy | Pathology |
|-------|-------------------|----------------|------------|---------------------|------------------|-----------|
| Mathews and Wilson | USA | Intrasellar | 41/male | Complete | NA | Chordoma |
| Slom and Konof onboard | USA | Preoptune | 26/male | Complete | None | Chordoma |
| Mapstone et al | USA | Suprasellar | 39/male | Complete | NA | Chordoma |
| Yuki et al | USA | Preoptune | 28/male | Complete | None | Chordoma |
| Wolle and Scheithauer | USA | Preoptune | 44/male | Procedure terminated | None | Chordoma |
| Mathews and Wilson | USA | Suprasellar | 28/male | Complete | Subtotal | Chordoma |
| Stam and Kamphorst | The Netherlands | Prepontine | 75/female | NA | NA | EP |
| Mapstone et al | USA | Prepontine | 26/male | Complete | None | Chordoma |
| Vaquero et al | USA | Suprasellar | 39/male | Complete | None | Chordoma |
| Yuhi et al | N/A | Prepontine | 28/male | NA | NA | Chordoma |
| Wolfe and Scheithauer | USA | Suprasellar | 44/male | Complete | None | Chordoma |
| Katayama et al | Japan | Foramen magnum | 30/female | Complete | None | Chordoma |
| Warnick et al | USA | Tentorium cerebelli | 58/male | Complete | None | Chordoma |
| Commins et al | USA | Hypothalamus | 51/male | Complete | None | Chordoma |
| Hardie | Japan | Preoptune | 49/male | Complete | None | Chordoma |
| Warick et al | USA | Preoptune | 51/male | Complete | None | Chordoma |
| Wanibuchi et al | Japan | Preoptune | 54/male | Complete | Subtotal | Chordoma |
| Atsumo et al | Japan | Preoptune | 51/male | Complete | Subtotal | Chordoma |
| Chen et al | Japan | Preoptune | 48/male | Complete | NA | Chordoma |
| Tozzi et al | Japan | Preoptune | 49/female | Complete | None | EP |
| Komai et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Iwama et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Masui et al | Japan | Preoptune | 51/female | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 51/female | Complete | None | Chordoma |
| Akimoto et al | Japan | Preoptune | 49/male | Complete | None | Chordoma |
| Nishigaya et al | Japan | Preoptune | 49/male | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 49/male | Complete | None | Chordoma |
| Tashiro | Japan | Preoptune | 49/male | Complete | None | Chordoma |
| Kato et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Uda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Akimoto et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Nishigaya et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Masui et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Uda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Akimoto et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Nishigaya et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Masui et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Uda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Akimoto et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Nishigaya et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Masui et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Uda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Akimoto et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Nishigaya et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Masui et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Uda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Akimoto et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Nishigaya et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Masui et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Uda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Akimoto et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Nishigaya et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Toda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Masui et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Uda et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Akimoto et al | Japan | Preoptune | 49/female | Complete | None | Chordoma |
| Study               | Country of origin | Tumor location                                      | Age, y/Sex | Extent of resection | Adjuvant therapy | Pathology               |
|---------------------|-------------------|-----------------------------------------------------|------------|---------------------|------------------|-------------------------|
| Chang et al^44      | USA               | Prepontine                                          | 9/male     | Complete            | None             | Chordoma                |
| Alkan et al^45      | Turkey            | Prepontine                                          | 22/male    | Subtotal            | None             | EP                      |
| Choo et al^46       | Korea             | Prepontine                                          | 43/female  | Subtotal            | SRS to residual | Chordoma                |
| Ciarpaglini et al^47| Italy             | Prepontine                                          | 60/male    | Subtotal            | None             | Chordoma                |
| Bergmann et al^15   | Germany           | Prepontine                                          | 76/male    | Subtotal            | None             | Chordoma                |
| Bhat et al^18       | India             | Prepontine                                          | 30/male    | Complete            | None             | Chordoma                |
| Ito et al^49        | Japan             | Prepontine                                          | 59/female  | Subtotal            | UNAC fXRT        | Chordoma                |
|                     | Japan             | Prepontine                                          | 75/female  | Complete            | Gamma knife SRS for recurrences only | Chordoma |
| Jiagang et al^50    | China             | Suprasellar                                         | 51/male    | Complete            | None             | Chordoma                |
| Figueiredo et al^51 | Brazil            | Pineal and intra-abdominal (history of VP shunt placement) | 18/male | Biopsy              | None             | Chordoma; prior surgery for presumed germinoma 7 y prior (histologic diagnosis revised) |
| Anderson et al^52   | USA               | Disseminated                                        | 13/female  | Subtotal            | fXRT             | Chordoma                |
| Kim et al^53        | Republic of Korea | Sellar-suprasellar                                   | 55/female  | Complete            | N/A              | Chordoma                |
| Wang et al^16       | China             | Prepontine                                          | 22/male    | Complete            | None             | Chordoma                |
|                     | China             | Prepontine                                          | 45/male    | Subtotal            | None             | Chordoma                |
|                     | China             | Prepontine                                          | 28/male    | Complete            | None             | Chordoma                |
|                     | China             | Prepontine                                          | 40/male    | Subtotal            | fXRT             | Chordoma                |
|                     | China             | Prepontine                                          | 41/female  | Subtotal            | fXRT             | Chordoma                |
|                     | China             | Prepontine                                          | 39/male    | Subtotal            | None             | Chordoma                |
| Current case        | Canada            | Petroclival                                         | 51/male    | Near-complete       | IMRT             | Chordoma                |

Abbreviations: EP, ecchordosis physaliphora; fXRT, fractionated radiotherapy; IMRT, intensity-modulated radiation therapy; NA, not available; SRS, stereotactic radiosurgery.